Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2020 | 09-2020 | 06-2020 | 03-2020 | 12-2019 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 496,580 | 496,704 | 580,829 | 467,779 | 547,178 |
| Marketable Securities | 1,377,815 | 1,337,172 | 1,344,735 | 874,424 | 988,984 |
| Receivables | 602,413 | 579,118 | 69,115 | 75,572 | 43,011 |
| Inventories | 75,202 | 66,942 | 77,418 | 68,300 | 56,348 |
| TOTAL | $2,614,777 | $2,554,702 | $2,160,446 | $1,584,773 | $1,715,864 |
| Non-Current Assets | |||||
| PPE Net | 465,029 | 444,690 | 439,126 | 429,814 | 425,179 |
| Investments And Advances | 40,725 | 24,725 | 24,725 | 24,725 | 14,825 |
| Other Non-Current Assets | 286,530 | 283,166 | 750,070 | 240,312 | 239,266 |
| TOTAL | $792,284 | $752,581 | $1,213,921 | $694,851 | $679,270 |
| Total Assets | $3,407,061 | $3,307,283 | $3,374,367 | $2,279,624 | $2,395,134 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 51,966 | 27,872 | 26,125 | 40,484 | 49,884 |
| Accrued Expenses | 355,909 | 295,260 | 211,186 | 183,221 | 197,201 |
| Other current liabilities | 13,316 | 10,316 | 5,957 | N/A | N/A |
| TOTAL | $585,270 | $480,241 | $384,302 | $338,791 | $352,594 |
| Non-Current Liabilities | |||||
| Long Term Debt | 191,278 | N/A | N/A | N/A | N/A |
| Deferred Revenues | 127,207 | 114,601 | 107,587 | 86,043 | 77,821 |
| Other Non-Current Liabilities | 1,389,172 | 1,346,311 | 1,308,809 | 284,980 | 285,465 |
| TOTAL | $1,805,544 | $1,612,019 | $1,590,339 | $591,104 | $603,848 |
| Total Liabilities | $2,390,814 | $2,092,260 | $1,974,641 | $929,895 | $956,442 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 117,002 | 116,181 | 115,970 | 114,819 | 112,584 |
| Common Shares | 1,164 | 1,161 | 1,156 | 1,131 | 1,122 |
| Retained earnings | -4,585,369 | -4,341,829 | -4,088,538 | -3,909,309 | -3,727,088 |
| Other shareholders' equity | -43,622 | -37,193 | -33,212 | -32,059 | -36,518 |
| TOTAL | $1,016,247 | $1,215,023 | $1,399,726 | $1,349,729 | $1,438,692 |
| Total Liabilities And Equity | $3,407,061 | $3,307,283 | $3,374,367 | $2,279,624 | $2,395,134 |